Lymphocyte phenotypes of subjects with stage 0 and stage 2 obesity*
| Phenotype | Stage 0(n=10) | Stage 2(n=9) |
| % of total cells | ||
| Total CD3+†,‡ | 53.6±22.9 | 58.9±19.0 |
| % of CD3+ cells that also express CD45RA+ | 39.6±9.8 | 62.4±19.1§ |
| CD3+CD4+ (Th cells) | 40.1±19.2 | 36.0±11.8 |
| CD3+CD8+ (cytotoxic T cells) | 14.4±3.8 | 21.0±6.9§ |
| CD4+CD25+†,‡ | 2.1±1.2 | 4.1±1.9 |
| CD8+CD25+† | 0.4±0.3 | 0.7±0.8 |
| CD3+CD4+CD25+FoxP3+ (T regulatory cells)†,‡ | 3.2±2.0 | 9.6±7.2 |
| Total CD278+‡ | 0.3±0.3 | 13.6±5.2§ |
| CD4+CD278+†,‡ | 0.3±0.2 | 10.1±7.0§ |
| Total CD80+ | 12.8±8.4 | 28.7±20.2§ |
| CD4+CD80+† | 3.8±3.0 | 8.7±8.9 |
| Total CD19+ (B cells) | 7.3±3.3 | 7.3±5.5 |
| % of CD19+ cells that also express CD80+† | 19.9±10.8 | 19.9±16.5 |
| Proportionate analysis of cells expressing CRTh2 | ||
| % of CD4+ cells that also express CRTh2 | 34.0±5.3 | 29.6±3.5 |
| % of CD8+ cells that also express CRTh2† | 18.5±5.0 | 24.0±9.1 |
| % of CD14+ cells that also express CRTh2† | 40.8±10.7 | 72.6±7.3§ |
| % of CD203c+ cells that also express CRTh2† | 46.2±7.1 | 35.8±6.8 |
| % of CCR3+ cells that also express CRTh2 | 99.0±0.4 | 99.2±0.2 |
*Values are presented as mean ± SD; Values are a proportion of the total gated cells as determined by immunofluorescence. No significant differences were observed among groups (N=19; mean ± SD) for total cells expressing CD4+ (34.5 ± 18.4), CD8+ (18.8 ± 7.9), CD25+ (5.3 ± 2.8), CD45RO+ (17.4 ± 10.8), CD71+† (3.1 ± 4.2) or CD4+CD45RO+ (6.7 ± 5.3), CD4+CD71+† (0.5 ± 0.4), CD8+CD71+†(0.4 ±0.4) cells and natural killer cells (CD3-CD56+† 5.0 ± 3.9).
†Analysis was performed on log-transformed values.
‡Significant correlation with age (n=19, p<0.05) and one-way ANOVA analysis adjusted for age as a confounding factor.
§Indicates mean within a row that is significantly different from the stage 0 obesity group using one-way ANOVA (p<0.05).
ANOVA, analysis of variance; CD, cluster of differentiation; CRTh2, chemoattractant-homologous receptor expressed on T helper 2 cells.